MITO

Stealth BioTherapeutics Corp. ADS
MITO

Delisted

MITO was delisted on the 15th of November, 2022.

Back to rankings

0 hedge funds and large institutions have $0 invested in Stealth BioTherapeutics Corp. ADS in 2022 Q4 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 12 closing their positions.

Upgrade to unlock
New
Increased
Maintained
Reduced
Closed

less funds holding

Funds holding: →

less capital invested

Capital invested by funds: $ → $

less first-time investments, than exits

New positions opened: | Existing positions closed:

Holders
–
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
–
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
–
Puts
–
Net Calls
Net Calls Change

Top Buyers

No buyers this quarter

Top Sellers

1
-$134K
2
-$54K
3
-$30K
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$15K
5
BFM
Boothbay Fund Management
New York
-$14K
Name Holding Trade Value Shares
Change 		Change in
Stake
IC
1
Ikarian Capital
Texas
–
BBHC
2
Brown Brothers Harriman & Co
New York
–
Renaissance Technologies
3
Renaissance Technologies
New York
–
Geode Capital Management
4
Geode Capital Management
Massachusetts
–
BFM
5
Boothbay Fund Management
New York
–
Susquehanna International Group
6
Susquehanna International Group
Pennsylvania
–
Envestnet Asset Management
7
Envestnet Asset Management
Illinois
–
CAPTRUST Financial Advisors
8
CAPTRUST Financial Advisors
North Carolina
–
Two Sigma Advisers
9
Two Sigma Advisers
New York
–
Osaic Holdings
10
Osaic Holdings
Arizona
–
AA
11
AlphaMark Advisors
Kentucky
–